News
The Manila Times on MSN27m
AstraZeneca eyes licensing lung cancer drugASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback